Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AT-02
- Development stage
- Phase 2
- Lead developer
- Attralus
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Administration
- Intravenous
01
Overview
AT-02 is a fusion protein of humanized immunoglobulin G1 (IgG1) with a pan-amyloid reactive peptide (p5R) designed to treat systemic amyloidosis. It works by binding to amyloid deposits and stimulating the immune system to remove them. AT-02 is being developed by Attralus for conditions like transthyretin-associated amyloidosis (ATTR) and immunoglobulin light-chain amyloidosis (AL).
- Other names
- zamubafusp alfaFC-Peptidep5-Fc fusion proteinp-5-Fc fusion proteinp 5-Fc fusion proteinhumanized IgG1-peptide fusion protein
02
Targets
Amyloid fibrils
Beyond the preview
Go deeper on AT-02.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AT-02.